CP101
Prevention of Recurrent C. difficile Infection (rCDI)
Phase 3Discontinued (Jan 2023)
Key Facts
Indication
Prevention of Recurrent C. difficile Infection (rCDI)
Phase
Phase 3
Status
Discontinued (Jan 2023)
Company
About Finch Therapeutics
Finch Therapeutics, founded in 2014, was a clinical-stage microbiome company that developed oral microbiome drugs. Its lead candidate, CP101, showed positive Phase 2 results for preventing recurrent C. difficile infection but its Phase 3 trial was discontinued in January 2023. The company has since shifted its strategy away from clinical development, undergoing delisting from Nasdaq and deregistration with the SEC in 2024, and is now focused on monetizing its IP portfolio and assets through partnerships.
View full company profile